Forte Biosciences Files 8-K Report
Ticker: FBRX · Form: 8-K · Filed: Dec 3, 2024 · CIK: 1419041
Sentiment: neutral
Topics: 8-K, corporate-filing, routine-report
TL;DR
Forte Bio filed an 8-K, standard update, no major news.
AI Summary
On December 3, 2024, Forte Biosciences, Inc. filed an 8-K report detailing other events and financial statements. The company, formerly known as Tocagen Inc., is incorporated in Delaware and headquartered in Dallas, Texas. The filing does not disclose specific financial figures or material events beyond its routine reporting.
Why It Matters
This filing serves as a routine update for investors and the public regarding Forte Biosciences' corporate status and financial reporting requirements.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not contain information indicating significant new risks or material adverse events.
Key Numbers
- 001-38052 — SEC File Number (Identifies the company's filing history with the SEC.)
- 26-1243872 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Forte Biosciences, Inc. (company) — Registrant
- Tocagen Inc. (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
- Dallas, Texas (location) — Principal executive offices
- December 3, 2024 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of December 3, 2024.
What was Forte Biosciences, Inc. formerly known as?
Forte Biosciences, Inc. was formerly known as Tocagen Inc.
In which state is Forte Biosciences, Inc. incorporated?
Forte Biosciences, Inc. is incorporated in Delaware.
What is the principal executive office address for Forte Biosciences, Inc.?
The principal executive office address is 3060 Pegasus Park Dr., Building 6, Dallas, Texas 75247.
What is the SEC file number for Forte Biosciences, Inc.?
The SEC file number for Forte Biosciences, Inc. is 001-38052.
Filing Stats: 469 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-12-03 16:31:40
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value FBRX The NASDAQ Stock Mar
Filing Documents
- d850569d8k.htm (8-K) — 25KB
- d850569dex991.htm (EX-99.1) — 50KB
- d850569dex992.htm (EX-99.2) — 42KB
- g850569ex99_1p10g1.jpg (GRAPHIC) — 191KB
- g850569ex99_1p11g1.jpg (GRAPHIC) — 170KB
- g850569ex99_1p12g1.jpg (GRAPHIC) — 331KB
- g850569ex99_1p13g1.jpg (GRAPHIC) — 84KB
- g850569ex99_1p14g1.jpg (GRAPHIC) — 190KB
- g850569ex99_1p15g1.jpg (GRAPHIC) — 215KB
- g850569ex99_1p16g1.jpg (GRAPHIC) — 137KB
- g850569ex99_1p17g1.jpg (GRAPHIC) — 166KB
- g850569ex99_1p18g1.jpg (GRAPHIC) — 182KB
- g850569ex99_1p19g1.jpg (GRAPHIC) — 52KB
- g850569ex99_1p1g1.jpg (GRAPHIC) — 98KB
- g850569ex99_1p20g1.jpg (GRAPHIC) — 202KB
- g850569ex99_1p21g1.jpg (GRAPHIC) — 144KB
- g850569ex99_1p22g1.jpg (GRAPHIC) — 173KB
- g850569ex99_1p23g1.jpg (GRAPHIC) — 66KB
- g850569ex99_1p24g1.jpg (GRAPHIC) — 260KB
- g850569ex99_1p25g1.jpg (GRAPHIC) — 364KB
- g850569ex99_1p26g1.jpg (GRAPHIC) — 127KB
- g850569ex99_1p27g1.jpg (GRAPHIC) — 278KB
- g850569ex99_1p28g1.jpg (GRAPHIC) — 60KB
- g850569ex99_1p29g1.jpg (GRAPHIC) — 280KB
- g850569ex99_1p2g1.jpg (GRAPHIC) — 540KB
- g850569ex99_1p30g1.jpg (GRAPHIC) — 53KB
- g850569ex99_1p31g1.jpg (GRAPHIC) — 275KB
- g850569ex99_1p32g1.jpg (GRAPHIC) — 201KB
- g850569ex99_1p33g1.jpg (GRAPHIC) — 215KB
- g850569ex99_1p34g1.jpg (GRAPHIC) — 309KB
- g850569ex99_1p35g1.jpg (GRAPHIC) — 257KB
- g850569ex99_1p36g1.jpg (GRAPHIC) — 234KB
- g850569ex99_1p37g1.jpg (GRAPHIC) — 68KB
- g850569ex99_1p38g1.jpg (GRAPHIC) — 180KB
- g850569ex99_1p39g1.jpg (GRAPHIC) — 47KB
- g850569ex99_1p3g1.jpg (GRAPHIC) — 272KB
- g850569ex99_1p40g1.jpg (GRAPHIC) — 262KB
- g850569ex99_1p41g1.jpg (GRAPHIC) — 279KB
- g850569ex99_1p42g1.jpg (GRAPHIC) — 184KB
- g850569ex99_1p43g1.jpg (GRAPHIC) — 240KB
- g850569ex99_1p44g1.jpg (GRAPHIC) — 230KB
- g850569ex99_1p45g1.jpg (GRAPHIC) — 266KB
- g850569ex99_1p46g1.jpg (GRAPHIC) — 55KB
- g850569ex99_1p47g1.jpg (GRAPHIC) — 273KB
- g850569ex99_1p48g1.jpg (GRAPHIC) — 386KB
- g850569ex99_1p49g1.jpg (GRAPHIC) — 220KB
- g850569ex99_1p4g1.jpg (GRAPHIC) — 307KB
- g850569ex99_1p50g1.jpg (GRAPHIC) — 293KB
- g850569ex99_1p51g1.jpg (GRAPHIC) — 180KB
- g850569ex99_1p52g1.jpg (GRAPHIC) — 52KB
- g850569ex99_1p53g1.jpg (GRAPHIC) — 267KB
- g850569ex99_1p54g1.jpg (GRAPHIC) — 319KB
- g850569ex99_1p55g1.jpg (GRAPHIC) — 240KB
- g850569ex99_1p56g1.jpg (GRAPHIC) — 195KB
- g850569ex99_1p57g1.jpg (GRAPHIC) — 58KB
- g850569ex99_1p58g1.jpg (GRAPHIC) — 137KB
- g850569ex99_1p59g1.jpg (GRAPHIC) — 48KB
- g850569ex99_1p5g1.jpg (GRAPHIC) — 281KB
- g850569ex99_1p60g1.jpg (GRAPHIC) — 272KB
- g850569ex99_1p6g1.jpg (GRAPHIC) — 68KB
- g850569ex99_1p7g1.jpg (GRAPHIC) — 263KB
- g850569ex99_1p8g1.jpg (GRAPHIC) — 55KB
- g850569ex99_1p9g1.jpg (GRAPHIC) — 177KB
- g850569ex99_2p10g1.jpg (GRAPHIC) — 280KB
- g850569ex99_2p11g1.jpg (GRAPHIC) — 84KB
- g850569ex99_2p12g1.jpg (GRAPHIC) — 190KB
- g850569ex99_2p13g1.jpg (GRAPHIC) — 215KB
- g850569ex99_2p14g1.jpg (GRAPHIC) — 137KB
- g850569ex99_2p15g1.jpg (GRAPHIC) — 166KB
- g850569ex99_2p16g1.jpg (GRAPHIC) — 182KB
- g850569ex99_2p17g1.jpg (GRAPHIC) — 81KB
- g850569ex99_2p18g1.jpg (GRAPHIC) — 231KB
- g850569ex99_2p19g1.jpg (GRAPHIC) — 59KB
- g850569ex99_2p1g1.jpg (GRAPHIC) — 110KB
- g850569ex99_2p20g1.jpg (GRAPHIC) — 280KB
- g850569ex99_2p21g1.jpg (GRAPHIC) — 53KB
- g850569ex99_2p22g1.jpg (GRAPHIC) — 276KB
- g850569ex99_2p23g1.jpg (GRAPHIC) — 201KB
- g850569ex99_2p24g1.jpg (GRAPHIC) — 215KB
- g850569ex99_2p25g1.jpg (GRAPHIC) — 309KB
- g850569ex99_2p26g1.jpg (GRAPHIC) — 257KB
- g850569ex99_2p27g1.jpg (GRAPHIC) — 234KB
- g850569ex99_2p28g1.jpg (GRAPHIC) — 68KB
- g850569ex99_2p29g1.jpg (GRAPHIC) — 180KB
- g850569ex99_2p2g1.jpg (GRAPHIC) — 540KB
- g850569ex99_2p30g1.jpg (GRAPHIC) — 47KB
- g850569ex99_2p31g1.jpg (GRAPHIC) — 262KB
- g850569ex99_2p32g1.jpg (GRAPHIC) — 279KB
- g850569ex99_2p33g1.jpg (GRAPHIC) — 184KB
- g850569ex99_2p34g1.jpg (GRAPHIC) — 240KB
- g850569ex99_2p35g1.jpg (GRAPHIC) — 230KB
- g850569ex99_2p36g1.jpg (GRAPHIC) — 266KB
- g850569ex99_2p37g1.jpg (GRAPHIC) — 54KB
- g850569ex99_2p38g1.jpg (GRAPHIC) — 273KB
- g850569ex99_2p39g1.jpg (GRAPHIC) — 386KB
- g850569ex99_2p3g1.jpg (GRAPHIC) — 272KB
- g850569ex99_2p40g1.jpg (GRAPHIC) — 220KB
- g850569ex99_2p41g1.jpg (GRAPHIC) — 293KB
- g850569ex99_2p42g1.jpg (GRAPHIC) — 180KB
- g850569ex99_2p43g1.jpg (GRAPHIC) — 52KB
- g850569ex99_2p44g1.jpg (GRAPHIC) — 267KB
- g850569ex99_2p45g1.jpg (GRAPHIC) — 319KB
- g850569ex99_2p46g1.jpg (GRAPHIC) — 240KB
- g850569ex99_2p47g1.jpg (GRAPHIC) — 195KB
- g850569ex99_2p48g1.jpg (GRAPHIC) — 48KB
- g850569ex99_2p49g1.jpg (GRAPHIC) — 272KB
- g850569ex99_2p4g1.jpg (GRAPHIC) — 307KB
- g850569ex99_2p5g1.jpg (GRAPHIC) — 281KB
- g850569ex99_2p6g1.jpg (GRAPHIC) — 68KB
- g850569ex99_2p7g1.jpg (GRAPHIC) — 263KB
- g850569ex99_2p8g1.jpg (GRAPHIC) — 184KB
- g850569ex99_2p9g1.jpg (GRAPHIC) — 94KB
- 0001193125-24-269949.txt ( ) — 30788KB
- fbrx-20241203.xsd (EX-101.SCH) — 3KB
- fbrx-20241203_lab.xml (EX-101.LAB) — 18KB
- fbrx-20241203_pre.xml (EX-101.PRE) — 11KB
- d850569d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FORTE BIOSCIENCES, INC. Date: December 3, 2024 By: /s/ Antony Riley Antony Riley Chief Financial Officer